Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Head & Neck Oncology
Published in: Head & Neck Oncology 1/2012

Open Access 01-12-2012 | Review

Systemic therapy in the management of metastatic or advanced salivary gland cancers

Authors: Aymen Lagha, Nesrine Chraiet, Mouna Ayadi, Sarra Krimi, Bassem Allani, Hela Rifi, Henda Raies, Amel Mezlini

Published in: Head & Neck Oncology | Issue 1/2012

Login to get access

Abstract

Salivary gland cancers are very rare tumors. They are characterized by a histologic heterogeneity and a poor outcome. According to this rarity, few prospective data are available to date. No standard recommendations could be held for the use of systemic therapy in these tumors. Several case reports and small studies have investigated the contribution of different agents of chemotherapy. With the extension of molecular biology approach in oncology several signaling pathways have been discovered in different cancers including salivary gland cancers; thus a number of targeted therapies have been investigated. This paper reviewed exhaustively the studies investigating the role of systemic therapies (chemotherapy, targeted therapy, hormone therapy) in salivary gland cancers.
Literature
1.
Laurie SA, Licitra L: Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006, 24: 2673-2678. 10.1200/JCO.2005.05.3025.CrossRefPubMed
2.
Guzzo M, Locati LD, Prott FJ, et al: Major and minor salivary gland tumors. Critical reviews in Oncology/Hematology. 2010, 74: 134-148. 10.1016/j.critrevonc.2009.10.004.CrossRefPubMed
3.
3-Tumours of the Salivary Glands. Pathology and Genetics of Head and Neck Tumours. Edited by: Barnes L, Eveson JW, Reichart P, Sidransky D. 2005, World Health Organization, Lyon, 209-
4.
Sung MW, Kim KH, Kim JW, et al: Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2003, 129: 1193-1197. 10.1001/archotol.129.11.1193.CrossRefPubMed
5.
Laurie SA: HO AL, Fury MG, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands : a systematic review. Lancet Oncol. 2011, 12: 815-824. 10.1016/S1470-2045(10)70245-X.CrossRefPubMed
6.
Terhaard CH, Lubsen H, Van der Tweel I, et al: Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck. 2004, 26: 681-692. 10.1002/hed.10400.CrossRefPubMed
7.
Licitra L, Marchini S, Spinazze S, et al: Cisplatin in advanced salivary gland carcinoma : a phase II study of 25 patients. Cancer. 1991, 68: 1874-1877. 10.1002/1097-0142(19911101)68:9<1874::AID-CNCR2820680904>3.0.CO;2-S.CrossRefPubMed
8.
Schramm VL, Scrodes C, Myers EN: Cisplatin therapy for adenoid cystic carcinoma. Arch Otolaryngol. 1981, 107: 739-741. 10.1001/archotol.1981.00790480015004.CrossRefPubMed
9.
De Haan LD, De Mulder PH, Vermorken JB, et al: Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck. Head neck. 1992, 14: 273-277. 10.1002/hed.2880140403.CrossRefPubMed
10.
Mattox DE, Von Hoff D, Balcerzak SP: Southwest oncology group study of Mitoxantrone for the treatment of patients with advanced adenoid cystic carcinoma of the head and neck. Invest new drugs. 1990, 8: 105-107.CrossRefPubMed
11.
Verweii J: de Mulder PM, de Graeff A et al. Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and neck Cancer Cooperative Group. Ann Oncol. 1996, 7: 867-869.
12.
Vermorken JB, Verweij J, de Mulder PH, et al: Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: A phase II study of the EORTC head and neck Cancer Cooperative Group. Ann Oncol. 1993, 4: 785-788.CrossRefPubMed
13.
14.
Kaplan MJ, Johns ME, Cantrell RW: Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg. 1986, 95: 165-170.CrossRefPubMed
15.
Airoldi M, Pedani F, Succo G, et al: Phase II randomised trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer. 2001, 91: 541-547. 10.1002/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO;2-Y.CrossRefPubMed
16.
Spiers ASD, Esseltine DLW, Ruckdeschel JC, Davies JNP, Horton J: Metastatic adenoid cystic carcinoma of salivary glands: case reports and review of literature. Cancer Control. 1996, 3 (4): 336-342.PubMed
17.
Tannock IF, Sutherland DJ: Chemotherapy for adenocystic carcinoma. Cancer. 1980, 46: 452-454. 10.1002/1097-0142(19800801)46:3<452::AID-CNCR2820460305>3.0.CO;2-Z.CrossRefPubMed
18.
Gilbert J, Li Y, Pinto HA, et al: Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck. 2006, 28: 197-204. 10.1002/hed.20327.CrossRefPubMed
19.
Raguse J, Gath HJ, Bier J, Riess H, Oettle H: Docetaxel (taxotere) in recurrent high grade mucoepidermoid carcinoma of the major salivary glands. Oral Oncology Extra. 2004, 40: 5-7. 10.1016/S1741-9409(03)00003-7.CrossRef
20.
Belli F, Di Lauro L, Zappanico A, Giunta S: Docetaxel in the treatment of metastatic carcinoma of the salivary glands report of a case. Clin Ter. 1999, 150 (1): 77-79.PubMed
21.
Van Herpen CM, Locati LD: Buter j, et al. Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). Eur J Cancer. 2008, 44: 2542-2545. 10.1016/j.ejca.2008.08.014.CrossRefPubMed
22.
Alberts DS, Manning MR, Coulthared SW, et al: Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer. 1981, 47: 645-648. 10.1002/1097-0142(19810215)47:4<645::AID-CNCR2820470404>3.0.CO;2-A.CrossRefPubMed
23.
Dreyfuss AI, Clark JR, Fallon BG, et al: Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer. 1987, 60: 2869-2872. 10.1002/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y.CrossRefPubMed
24.
Belani CP, Eisenberger MA, Gray WC: Preliminary experience with chemotherapy in advanced salivary gland neoplasms. Med Pediatr Oncol. 1988, 16: 197-202. 10.1002/mpo.2950160309.CrossRefPubMed
25.
Creagan ET, Woods JE, Rubin J, et al: Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Cancer. 1988, 62: 2313-2319. 10.1002/1097-0142(19881201)62:11<2313::AID-CNCR2820621110>3.0.CO;2-4.CrossRefPubMed
26.
Licitra L, Cavina R, Grandi C, et al: Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma : aphase II trial of 22 patients. Ann Oncol. 1996, 7: 640-642. 10.1093/oxfordjournals.annonc.a010684.CrossRefPubMed
27.
Eisenberger MA: Supporting evidence for an active treatment program for advanced salivary gland carcinoma. Cancer Treat Rep. 1985, 69: 319-321.PubMed
28.
Venook AP, Tseng A, Meyers FJ, et al: Cisplatin, doxorubicin and 5-fluoruracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol. 1987, 5: 951-955.PubMed
29.
Dimery IW, Legha SS, Shirinian L, et al: Fluorouracil, doxorubicin, cyclophosphamide and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J clin Oncol. 1990, 8: 1056-1062.PubMed
30.
Airoldi M, Pedani F, Brando V, et al: Cisplatin, epirubicin anf 5-fluouracil combination chemotherapy for recurrent carcinoma of the salivary gland. Tumori. 1989, 75: 252-256.PubMed
31.
Ross PJ, Teoh EM, A’Hern RP, et al: Epirubicin, cisplatin and protacted venous infusion 5-fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma. Clin Oncol (R Coll Radiol). 2009, 21: 311-314. 10.1016/j.clon.2008.12.009.CrossRef
32.
Tsukuda M, Kokatsu T, Ito K, et al: Chemotherapy for recurrent adeno and adenoidcystic carcinomas in the head and neck. J cancer Res Clin Oncol. 1993, 119: 756-758. 10.1007/BF01195348.CrossRefPubMed
33.
Posner MR, Ervin TJ, Weichselbaum RR, et al: Chemotherapy for advanced salivary gland neoplasms. Cancer. 1982, 50: 2261-2264. 10.1002/1097-0142(19821201)50:11<2261::AID-CNCR2820501105>3.0.CO;2-E.CrossRefPubMed
34.
Triozzi PL, Brantley A, Fisher S, et al: Fluoruracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck. Cancer. 1987, 59: 887-890. 10.1002/1097-0142(19870301)59:5<887::AID-CNCR2820590505>3.0.CO;2-8.CrossRefPubMed
35.
Hill ME, Constenla DO, A’Hern RP, et al: Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol. 1997, 33: 275-278. 10.1016/S0964-1955(97)00026-2.CrossRefPubMed
36.
Airoldi M, Fornari G, Fedani F, et al: Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res. 2000, 20: 3781-3783.PubMed
37.
Ruzich JC, Ciesla MC, Clark JL: Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report. Head Neck. 2002, 24: 406-410. 10.1002/hed.10034.CrossRefPubMed
38.
Gedlicka C, Schull B, Formanek M, et al: Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies. Anticancer Drugs. 2002, 13: 491-495. 10.1097/00001813-200206000-00007.CrossRefPubMed
39.
Laurie SA, Siu LL, Winquist E, et al: A phase II study of platinium and gemcitabine in advanced salivary gland cancers : a trial of the NCIC Clinical trials Group. Cancer. 2010, 116: 362-368. 10.1002/cncr.24745.CrossRefPubMed
40.
Jones AS, Phillips DE, Cook JA, Helliwell TR: A randomized phase II trial of Epirubicin and 5-Fluorouracil versus Cisplatinum in the palliation of advanced and recurrent malignant tumor of the salivary glands. Br J Cancer. 1993, 67: 112-114. 10.1038/bjc.1993.19.PubMedCentralCrossRefPubMed
41.
Pedani F, Airoldi M, Marchionatti S, Bumma C: Cisplatin+irinotecan in recurrent/metastatic salivary gland malignancies. European Journal of Cancer Supplements. 2003, 1 (5): S44--CrossRef
42.
Mino M, Pilch BZ, Faquin WC: Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma. Mod Pathol. 2003, 16 (12): 1224-1231. 10.1097/01.MP.0000096046.42833.C7.CrossRefPubMed
43.
Dodd RL, Slevin NJ: Salivary gland adenoid cystic carcinoma: A review of chemotherapy and molecular therapies. Oral Oncology. 2006, 42: 759-769. 10.1016/j.oraloncology.2006.01.001.CrossRefPubMed
44.
Holst VA, Marshall CE, Moskaluk CA, et al: Kit protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol. 1999, 12: 956-960.PubMed
45.
Jeng YM, Lin CY, Hsu HC: Expression of the c-kit protein is associated with certain sub-types of salivary gland carcinoma. Cancer Lett. 2000, 154: 107-111. 10.1016/S0304-3835(00)00387-6.CrossRefPubMed
46.
Edwards PC, Bhuiya T, Kelsch RD: C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003, 95 (5): 586-593. 10.1067/moe.2003.31.CrossRefPubMed
47.
Penner CR, Folpe AL, Budnick SD: C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod Pathol. 2002, 15 (7): 687-691. 10.1097/01.MP.0000018973.17736.F8.CrossRefPubMed
48.
Oliveira AM, Hornick JL, Duensing A, Medeiros F, Fletcher CDM, Fletcher JA: KIT expression and activation in adenoid cystic carcinoma [abstract]. Mod Pathol. 2003, 16: 221A-
49.
Guigay JM, Bidault F, Temam S, Janot F, Raymond E, Faivre S: Antitumor activity of imatinib in progressive, highly expressing KIT adenoid cystic carcinoma of the salivary glands: a phase II study. Proc Am Soc Clin Oncol. 2007, 25: abstr 6086-
50.
Slevin NJ, Mais KL, Bruce I: Imatinib with cisplatin in recurrent and/or metastatic adenoidcystic carcinoma-preliminary results of a phase II study of 18 patients with response assessed by morphological and functional imaging. Eur J Cancer Supplements. 2005, 3: 292-293.
51.
Ochel HJ, Gademann G, Rocken C, Wordehoff H: Eff ects of imatinib mesylate on adenoid cystic carcinomas. Anticancer Res. 2005, 25: 3659-3664.PubMed
52.
Lin CH, Yen RF, Jeng YM, Tzen CY, Hsu C, Hong RL: Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. Head Neck. 2005, 27: 1022-1027. 10.1002/hed.20274.CrossRefPubMed
53.
Hotte SJ, Winquist EW, Lamont E, et al: Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol. 2005, 23: 585-590.CrossRefPubMed
54.
Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M: A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 2007, 43: 33-36. 10.1016/j.oraloncology.2005.12.026.CrossRefPubMed
55.
Alcedo JC, Fabrega JM, Arosemena JR, et al: Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck. 2004, 26: 829-831. 10.1002/hed.20094.CrossRefPubMed
56.
Faivre S, Raymond E, Casiraghi O, et al: Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol. 2005, 23: 6273-6274. 10.1200/JCO.2005.01.6592. author replyCrossRef
57.
Vered M, Braunstein E, Buchner A: Immmunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck. 2002, 24: 632-636. 10.1002/hed.10104.CrossRefPubMed
58.
Glisson B, Blumenschein G, Francisco H, et al: Phase II trial of gefitinib in patients with incurable salivary gland cancer. Proc Am Soc Clin Oncol. 2005, 23: abstr 5532-
59.
Agulnik M, Cohen EW, Cohen RB, et al: Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007, 25 (25): 3978-3984. 10.1200/JCO.2007.11.8612.CrossRefPubMed
60.
Locati LD, Bossi P, Perrone F, et al: Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol. 2009, 45: 574-578. 10.1016/j.oraloncology.2008.07.010.CrossRefPubMed
61.
Giannoni C, El-Naggar AK, Ordnoez NG, Tu ZN, Austin J, Luna MA, Batsakis JG: C-erbB-2/neu oncogene and Ki67 analysis in the assessment of palatal salivary gland neoplasms. Otolaryngol. Head Neck Surg. 1995, 112: 391-398. 10.1016/S0194-5998(95)70272-5.CrossRefPubMed
62.
Shintani S, Funayama T, Yoshihama Y, Alcalde RE, Ootsuki K, Terakado N, Matsumura T: Expression of C-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study. Anticancer Res. 1995, 15: 2623-2626.PubMed
63.
Khan AJ, Digiovanna MP, Ross DA, Sasaki CT, Carter D, Son YH, Haffty BG: Adenoid cystic carcinoma: a retrospective clinical review. Int. J. Cancer. 2001, 96: 149-158. 10.1002/ijc.1013.CrossRefPubMed
64.
Glisson B, Colevas AD, Haddad R, et al: HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004, 10 (3): 944-946. 10.1158/1078-0432.CCR-03-0253.CrossRefPubMed
65.
Dori S, Vered M, David R, et al: HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. J Oral Pathol Med. 2002, 31: 463-467. 10.1034/j.1600-0714.2002.00017.x.CrossRefPubMed
66.
Cho KJ, Lee SS, Lee YS: Proliferating cell nuclear antigen and C-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands. Head Neck. 1999, 21: 414-419. 10.1002/(SICI)1097-0347(199908)21:5<414::AID-HED6>3.0.CO;2-M.CrossRefPubMed
67.
Karja V, Syrjanen S, Kataja V, Syrjanen K: C-erbB-2 oncogene expression in salivary gland tumours. ORL J Otorhinolaryngol Relat Spec. 1994, 56 (4): 206-212. 10.1159/000276657.CrossRefPubMed
68.
Kerhonan NM, Blessing K, King G, Corbett IP, Miller ID: Expression of c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. J Pathol. 1991, 163 (1): 77-80. 10.1002/path.1711630113.CrossRef
69.
Sugano S, Mukai K, Tsuda H, Hirohashi S, Furuya S, Shimosato Y, et al: Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope. 1992, 102 (8): 923-927. 10.1288/00005537-199208000-00013.CrossRefPubMed
70.
Kusafuka K: Expressions of oncogene products in adenoid cystic carcinomas of salivary glands: immunohistochemical study. Kobubyo Gakkai Zasshi. 1991, 58 (4): 696-717. 10.5357/koubyou.58.696.CrossRef
71.
Press MF, Pike MC, Hung G, et al: Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 1994, 54 (21): 5675-5682.PubMed
72.
Weed DT, Gomez-Fernandez C, Pacheco J, et al: MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma. Head Neck. 2004, 26 (4): 353-364. 10.1002/hed.10387.CrossRefPubMed
73.
Gibbons MD, Manne U, Carroll WR, Peters GE, Weiss HL, Grizzle WE: Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope. 2001, 111 (8): 1373-1378. 10.1097/00005537-200108000-00011.CrossRefPubMed
74.
Shrestha P, Huang JW, Tsuji T, Shinozaki F, Maeda K, Sasaki K, et al: Rare expression of the c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. J Oral Pathol Med. 1992, 21: 477-480. 10.1111/j.1600-0714.1992.tb00978.x.CrossRefPubMed
75.
Jaehne M, Roeser K, Jaekel T, et al: Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer. 2005, 103 (12): 2526-2533. 10.1002/cncr.21116.CrossRefPubMed
76.
Nabili V, Tan JW, Bhuta S, et al: Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck. 2007, 29 (10): 907-912. 10.1002/hed.20614.CrossRefPubMed
77.
Haddad R, Colevas AD, Krane JF, et al: Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003, 39 (7): 724-727. 10.1016/S1368-8375(03)00097-6.CrossRefPubMed
78.
Prat A, Parera M, Reyes V, et al: Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck. 2008, 30 (5): 680-683. 10.1002/hed.20714.CrossRefPubMed
79.
Nashed M, Casasola RJ: Biological therapy of salivary duct carcinoma. J Laryngol Otol. 2009, 123 (2): 250-252. 10.1017/S0022215108002314.CrossRefPubMed
80.
Kaidar-Person O, Billan S, Kuten A: Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Med Oncol. 2011, Mar 6 [Epub ahead of print]
81.
Zhang J, Peng B, Chen X: Expressions of nuclear factor kappa B, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res. 2005, 11 (20): 7334-7343. 10.1158/1078-0432.CCR-05-0241.CrossRefPubMed
82.
Zhang J, Peng B: NF-kappaB promotes iNOS and VEGF expression in salivary gland adenoid cystic carcinoma cells and enhances endothelial cell motility in vitro. Cell Prolif. 2009, 42: 150-161. 10.1111/j.1365-2184.2009.00588.x.CrossRefPubMed
83.
Argiris A, Ghebremichael M, Burtness B, et al: A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303). Cancer. 2011, 117: 3374-3382. 10.1002/cncr.25852.PubMedCentralCrossRefPubMed
84.
Dori S, Trougouboff P, David R, Buchner A: Immunohistochemical evaluation of estrogen and progesterone receptors in adenoid cystic carcinoma of salivary gland origin. Oral Oncol. 2000, 36: 450-453. 10.1016/S1368-8375(00)00029-4.CrossRefPubMed
85.
Miller AS, Hartman GG, Chen SY, Edmonds PR, Brightman SA, Harwick RD: Estrogen receptor assay in polymorphous lowgrade adenocarcinoma and adenoid cystic carcinoma of salivary gland origin. An immunohistochemical study. Oral Surg Oral Med Oral Pathol. 1994, 77 (1): 36-40. 10.1016/S0030-4220(06)80104-0.CrossRefPubMed
86.
Gaffney EV, Pinkston JA, Eidson JJ: Estrogen receptors in parotid tumors. Endocr Res. 1995, 21: 635-643. 10.3109/07435809509030479.CrossRefPubMed
87.
Pires FR, Perez DE, Almeida OP, Kowalski LP: Estrogen receptor expression in salivary gland mucoepidermoid carcinoma and adenoid cystic carcinoma. Pathol Oncol Res. 2004, 10 (3): 166-168. 10.1007/BF03033746.CrossRefPubMed
88.
Dimery IW, Jones LA, Verjan RP, Raymond AK, Goepfert H, Hong WK: Estrogen receptors in normal salivary gland and salivary gland carcinoma. Arch Otolaryngol Head Neck Surg. 1987, 113: 1082-1085. 10.1001/archotol.1987.01860100060022.CrossRefPubMed
89.
Shick PC, Riordan GP, Foss RD: Estrogen and progesterone receptors in salivary gland adenoid cystic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995, 80 (4): 440-444. 10.1016/S1079-2104(05)80338-5.CrossRefPubMed
90.
Jeannon JP, Soames JV, Bell H, Wilson JA: Immunohistochemical detection of oestrogen and progesterone receptors in human salivary gland tumours. Clin Otolaryngol. 1999, 24 (1): 52-54. 10.1046/j.1365-2273.1999.00211.x.CrossRefPubMed
91.
Ozono S, Onozuka M, Sato K, Ito Y: Immunohistochemical localization of estradiol, progesterone, and progesterone receptor in human salivary glands and salivary adenoid cystic carcinomas. Cell Struct Funct. 1992, 17: 169-175. 10.1247/csf.17.169.CrossRefPubMed
92.
Fan CY, Melhem MF, Hosal AS, et al: Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg. 2001, 127 (9): 1075-1079. 10.1001/archotol.127.9.1075.CrossRefPubMed
93.
Shadaba A, Gaze MN, Grant HR: The response of adenoid cystic carcinoma to tamoxifen. J Laryngol. 1997, 111 (12): 1186-1189.CrossRef
94.
Elkin AD, Jacobs CD: Tamoxifen for salivary gland adenoid cystic carcinoma: a report of two cases. J Cancer Res Clin Oncol. 2008, 134: 1151-1153. 10.1007/s00432-008-0377-3.CrossRefPubMed
95.
Locati LD, Quattrone P, Bossi P, et al: A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol. 2003, 14 (8): 1327-1328. 10.1093/annonc/mdg331.CrossRefPubMed
96.
Van der Hulst RW, Van Krieken JH, Van der Kwast TH, et al: Partial remission of parotid gland carcinoma after goserelin. Lancet. 1994, 344: 817-CrossRefPubMed
97.
Metadata
Title
Systemic therapy in the management of metastatic or advanced salivary gland cancers
Authors
Aymen Lagha
Nesrine Chraiet
Mouna Ayadi
Sarra Krimi
Bassem Allani
Hela Rifi
Henda Raies
Amel Mezlini
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Head & Neck Oncology / Issue 1/2012
Electronic ISSN: 1758-3284
DOI
https://doi.org/10.1186/1758-3284-4-19

Other articles of this Issue 1/2012

Head & Neck Oncology 1/2012 Go to the issue

Research

Definitive radiotherapy for early stage glottic cancer by 6 MV photons

Research

The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, medicare, and medicaid

Research

Knockdown of aberrantly expressed nuclear localized decorin attenuates tumour angiogenesis related mediators in oral cancer progression model in vitro

Research

Reconstruction of scalp defects with the radial forearm free flap

Research

Positron emission tomography in the detection of occult primary head and neck carcinoma: a retrospective study

Review

A review of the epidemiology of oral and pharyngeal carcinoma: update
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits